Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 1
1987 1
1988 1
1989 1
1993 1
1995 1
1996 5
1997 3
1998 2
1999 1
2001 3
2002 1
2003 4
2004 7
2005 7
2006 7
2007 7
2008 6
2009 2
2010 6
2011 5
2012 5
2013 7
2014 5
2015 5
2016 1
2017 8
2018 1
2019 4
2021 4
2022 11
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, Heerspink HJL, Hugo C, Nangaku M, Rotter RC, Silva A, Shah SV, Sun Z, Urbach D, de Zeeuw D, Rossing P; ASi in CKD group. Tuttle KR, et al. Lancet. 2024 Jan 27;403(10424):379-390. doi: 10.1016/S0140-6736(23)02408-X. Epub 2023 Dec 15. Lancet. 2024. PMID: 38109916 Clinical Trial.
Hyperprolactinemia and insulin resistance.
Gierach M, Bruska-Sikorska M, Rojek M, Junik R. Gierach M, et al. Among authors: junik r. Endokrynol Pol. 2022;73(6):959-967. doi: 10.5603/EP.a2022.0075. Endokrynol Pol. 2022. PMID: 36621922 Free article. Review.
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators. Dormandy JA, et al. Lancet. 2005 Oct 8;366(9493):1279-89. doi: 10.1016/S0140-6736(05)67528-9. Lancet. 2005. PMID: 16214598 Free article. Clinical Trial.
PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection.
Navarese EP, Podhajski P, Gurbel PA, Grzelakowska K, Ruscio E, Tantry U, Magielski P, Kubica A, Niezgoda P, Adamski P, Junik R, Przybylski G, Pilaczyńska-Cemel M, Rupji M, Specchia G, Pinkas J, Gajda R, Gorog DA, Andreotti F, Kubica J. Navarese EP, et al. Among authors: junik r. J Am Coll Cardiol. 2023 Jan 24;81(3):224-234. doi: 10.1016/j.jacc.2022.10.030. J Am Coll Cardiol. 2023. PMID: 36653090 Free PMC article. Clinical Trial.
Insulin resistance and thyroid disorders.
Gierach M, Gierach J, Junik R. Gierach M, et al. Among authors: junik r. Endokrynol Pol. 2014;65(1):70-6. doi: 10.5603/EP.2014.0010. Endokrynol Pol. 2014. PMID: 24549605 Free article. Review.
Is Restless Legs Syndrome De Facto Thyroid Disease?
Suwała S, Rzeszuto J, Glonek R, Krintus M, Junik R. Suwała S, et al. Among authors: junik r. Biomedicines. 2022 Oct 7;10(10):2502. doi: 10.3390/biomedicines10102502. Biomedicines. 2022. PMID: 36289762 Free PMC article.
National Program of Severe Growth Hormone Deficiency Treatment in Adults and Adolescents after Completion of Growth Promoting Therapy.
Lewiński A, Smyczyńska J, Stawerska R, Hilczer M, Stasiak M, Bednarczuk T, Bolanowski M, Junik R, Ruchała M, Syrenicz A, Walczak M, Zgliczyński W, Karbownik-Lewińska M. Lewiński A, et al. Among authors: junik r. Endokrynol Pol. 2018;69(5):468-524. doi: 10.5603/EP.a2018.0054. Epub 2018 Aug 17. Endokrynol Pol. 2018. PMID: 30117531 Free article. Review.
130 results